News

The coming of age for CDK 4/6 inhibitors

1 Mar 2017
The coming of age for CDK 4/6 inhibitors

Invitation to all St Gallen 2017 delegates

The ecancer team is proud to be hosting a special educational event at the forthcoming St Gallen International Breast Cancer Conference in Vienna on the 15th March on the coming of age for CDK 4/6 inhibitors. 

The event is free to all delegates from the conference and will be chaired by Giuseppe Curigliano from the European Institute of Oncology, Milan, Italy

The session is being held in Hall ABC, Austria Center, Vienna. If you are attending St Gallen, please join us at 8am for a free networking breakfast. Catch up with oncology colleagues and meet the symposium faculty over a hot drink and pastry.

The Symposium will start at 8.30am and will give you the latest emerging evidence for the optimal integration of new therapies into treatment plans. The session will cover:

What are CDKs?
Ghadeer Shubassi, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan, Italy

CDK inhibitors in clinical practice and under development
Pierfranco Conte, Veneto Institute of Oncology, Padova, Italy

Clinical trial results: the benefits, side effects and costs​
Harold Burstein, Dana-Faber Cancer Institute, Boston, USA

We look forward to seeing you in Vienna.

If you would like more information about this event please email karen@ecancer.org